Nykredit A S Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Nykredit A/S acquired 43,641 shares of Alnylam Pharmaceuticals in the second quarter, valued at approximately $13.1 million. Institutional investors collectively own 92.97% of the company.
• Analysts remain broadly positive, with Alnylam receiving a “Moderate Buy” consensus rating and an average price target of $367.20, despite several recent target reductions.
• Alnylam exceeded quarterly EPS expectations with $1.84 versus $1.63 forecast, while revenue rose 66.9% year over year to $1.29 billion, slightly below estimates.

Nykredit A S purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 43,641 shares of the biopharmaceutical company's stock, valued at approximately $13,137,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Norges Bank acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $895,816,000. Legal & General Group Plc bought a new stake in Alnylam Pharmaceuticals during the second quarter valued at $278,321,000. Bank of New York Mellon Corp acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $148,128,000. Canada Pension Plan Investment Board acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $100,618,000. Finally, Korea Investment CORP bought a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $74,553,000. 92.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ALNY has been the topic of several recent research reports. Bank of America cut their price target on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a "buy" rating on the stock in a report on Tuesday, July 14th. Royal Bank Of Canada cut their price objective on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an "outperform" rating on the stock in a report on Friday, July 31st. Chardan Capital restated a "buy" rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. HC Wainwright reaffirmed a "buy" rating and issued a $455.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 2nd. Finally, Citigroup decreased their price objective on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a "buy" rating for the company in a research note on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $367.20.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $239.56 on Monday. The stock has a market cap of $32.06 billion, a PE ratio of 44.53 and a beta of 0.31. The company's fifty day moving average is $247.29 and its 200 day moving average is $285.63. Alnylam Pharmaceuticals, Inc. has a 52 week low of $197.81 and a 52 week high of $495.55. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts' consensus estimates of $1.63 by $0.21. The firm had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The business's quarterly revenue was up 66.9% compared to the same quarter last year. During the same period last year, the company earned ($0.51) EPS. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.71 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam's commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.